With a different approach using a high-throughput drug library screening methodology, more than 4,000 compounds were screened at various final concentrations on two primary AML patient samples with MLL-AF9 translocation aiming to identify drugs that can achieve inhibition of more than 50% leukemic cell viability. The gene discussed is MLLT3; the disease is acute myeloid leukemia.